Aspen Pharmacare expects an improvement in earnings for the year to June following the devaluation of its Venezuelan business in the previous year, among other factors. On Wednesday, the company said the increase in earnings was lifted by the one-off negative effect in the same period a year earlier arising from the devaluation of Aspen’s Venezuelan business. There had also been higher intangible asset impairments, which were offset by capital profits realised from the disposal of noncore businesses and products.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.